TY - JOUR
T1 - Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma
T2 - A retrospective study
AU - Gardini, Andrea Casadei
AU - Foca, Flavia
AU - Scartozzi, Mario
AU - Silvestris, Nicola
AU - Tamburini, Emiliano
AU - Faloppi, Luca
AU - Brunetti, Oronzo
AU - Rudnas, Britt
AU - Pisconti, Salvatore
AU - Valgiusti, Martina
AU - Marisi, Giorgia
AU - Foschi, Francesco Giuseppe
AU - Ercolani, Giorgio
AU - Tassinari, Davide
AU - Cascinu, Stefano
AU - Frassineti, Giovanni Luca
PY - 2017/2/13
Y1 - 2017/2/13
N2 - Preliminary studies suggest that capecitabine may be safe and effective in HCC patients. The aim of this study was to retrospectively evaluate the safety and efficacy of metronomic capecitabine as second-line treatment. This multicentric study retrospectively analyzed data of HCC patients unresponsive or intolerant to sorafenib treatment with metronomic capecitabine or best supportive care (BSC).Median progression free survival was 3.1 months in patients treated with capecitabine (95%CI: 2.7-3.5). Median overall survival was 12.0 months (95% CI: 10.7-15.8) in patients receiving capecitabine, while 9.0 months (95% CI: 6.5-13.9) in patients receiving BSC. The result of univariate unweighted Cox regression model shows a 46% reduction in death risk for patients on capecitabine (95%CI: 0.357-0.829; p=0.005) compared to patients receiving BSC alone. After weighting for potential confounders, death risk remained essentially unaltered (45%; 95%CI: 0.354-0.883; p = 0.013). Metronomic capecitabine seems a safe second-line treatment for HCC patients in terms of management of adverse events, showing a potential anti-tumour activity which needs further evaluation in phase III studies.
AB - Preliminary studies suggest that capecitabine may be safe and effective in HCC patients. The aim of this study was to retrospectively evaluate the safety and efficacy of metronomic capecitabine as second-line treatment. This multicentric study retrospectively analyzed data of HCC patients unresponsive or intolerant to sorafenib treatment with metronomic capecitabine or best supportive care (BSC).Median progression free survival was 3.1 months in patients treated with capecitabine (95%CI: 2.7-3.5). Median overall survival was 12.0 months (95% CI: 10.7-15.8) in patients receiving capecitabine, while 9.0 months (95% CI: 6.5-13.9) in patients receiving BSC. The result of univariate unweighted Cox regression model shows a 46% reduction in death risk for patients on capecitabine (95%CI: 0.357-0.829; p=0.005) compared to patients receiving BSC alone. After weighting for potential confounders, death risk remained essentially unaltered (45%; 95%CI: 0.354-0.883; p = 0.013). Metronomic capecitabine seems a safe second-line treatment for HCC patients in terms of management of adverse events, showing a potential anti-tumour activity which needs further evaluation in phase III studies.
UR - http://www.scopus.com/inward/record.url?scp=85012294463&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85012294463&partnerID=8YFLogxK
U2 - 10.1038/srep42499
DO - 10.1038/srep42499
M3 - Article
AN - SCOPUS:85012294463
VL - 7
JO - Scientific Reports
JF - Scientific Reports
SN - 2045-2322
M1 - 42499
ER -